Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Sign Up to like & getrecommendations! Published in 2022 at "Dermatology and Therapy"
DOI: 10.1007/s13555-022-00713-1
Abstract: There is an increasing trend of malignancy worldwide. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones for the treatment of immune-mediated inflammatory diseases (IMIDs), but risk of malignancy is a major concern for patients receiving DMARDs.… read more here.
Keywords: conventional synthetic; antirheumatic drugs; disease modifying; oral conventional ... See more keywords
Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13244
Abstract: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported outcomes in Chinese patients with… read more here.
Keywords: tofacitinib conventional; conventional synthetic; disease modifying; synthetic disease ... See more keywords
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "RMD Open"
DOI: 10.1136/rmdopen-2016-000410
Abstract: Objectives To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. Methods In this phase III… read more here.
Keywords: baricitinib; reported outcomes; conventional synthetic; study ... See more keywords
Myocardial extracellular volume fraction quantification in an animal model of the doxorubicin-induced myocardial fibrosis: a synthetic hematocrit method using 3T cardiac magnetic resonance.
Sign Up to like & getrecommendations! Published in 2021 at "Quantitative imaging in medicine and surgery"
DOI: 10.21037/qims-20-501
Abstract: Background Visualization of diffuse myocardial fibrosis is challenging and mainly relies on histology. Cardiac magnetic resonance (CMR), which uses extracellular contrast agents, is a rapidly developing technique for measuring the extracellular volume (ECV). The objective… read more here.
Keywords: ecv; conventional synthetic; myocardial fibrosis; synthetic ecv ... See more keywords
Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2019.01214
Abstract: Background: The therapy with biological disease-modifying anti-rheumatic drugs (bDMARDs) has proven to rapidly reduce articular symptoms/signs, decrease morbidities, and improve health outcome in patients with rheumatoid arthritis (RA) and be cost-effective in Western countries. However,… read more here.
Keywords: cohort; conventional synthetic; healthcare utilization; utilization costs ... See more keywords
Edible Biopolymers-Based Materials for Food Applications—The Eco Alternative to Conventional Synthetic Packaging
Sign Up to like & getrecommendations! Published in 2021 at "Polymers"
DOI: 10.3390/polym13213779
Abstract: The problem of waste generated by packaging obtained from conventional synthetic materials, often multilayer, has become more and more pressing with increasing consumption. In this context, nature and humanity have suffered the most. In order… read more here.
Keywords: conventional synthetic; edible biopolymers; biopolymers based; packaging ... See more keywords